<DOC>
	<DOCNO>NCT00972335</DOCNO>
	<brief_summary>In multicenter , Phase II trial , investigator plan evaluate activity combination bevacizumab everolimus patient recurrent , progressive meningioma follow maximal treatment surgical resection local radiation therapy . Although patient relatively rare , currently establish standard treatment disease cause great deal morbidity , eventually fatal .</brief_summary>
	<brief_title>Trial Combination Bevacizumab Everolimus Patients With Refractory , Progressive Intracranial Meningioma</brief_title>
	<detailed_description />
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients must 18 year age . 2 . Histologic diagnosis meningioma , WHO grade 1 , 2 , 3 ( benign , atypical , malignant ) . In addition , patient definitive radiologic evidence meningioma unresectable , radiation therapy without biopsy standard treatment , also eligible . 3 . All patient must develop recurrent disease/progression receive standard treatment , must include follow : surgical resection , possible ; definitive radiation therapy unresectable meningioma , recurrent meningioma resection . patient must least 4 week postsurgery , must least 2 week postradiation therapy , resolution related toxicity . 4 . All patient must progressive symptom judge directly relate recurrent/progressive meningioma . Patients new symptom , patient stable neurologic deficit previous surgical resection , eligible . 5 . Patients may 0 1 previous systemic treatment regimen . 6 . ECOG performance status 02 . 7 . Adequate bone marrow , kidney , liver function , follow : Absolute neutrophil count ( ANC ) ≥1500/μL Hemoglobin ( Hgb ) ≥9 g/dL Platelets ≥100,000/L ( ≤7 day prior treatment ) AST ALT ≤2.5 x institutional upper limit normal ( ULN ) Total bilirubin ≤1.5 x institutional ULN Serum creatinine ≤1.5 x institutional ULN 8 . Life expectancy least 12 week . 9 . Ability swallow whole pill . 10 . Patients must measurable disease MRI scan . 11 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Women childbearing potential men partner childbearing potential must use effective birth control measure treatment . If woman become pregnant suspect pregnant participate study , must agree inform treat physician immediately . 12 . INR ≤1.5 x institutional upper limit normal ( ULN ) . ( Anticoagulation allow target INR ≤1.5 stable dose warfarin stable dose LMW heparin &gt; 2 week time study entry ) . 13 . Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fast triglyceride ≤2.5 x institutional ULN . Note : In case one threshold exceed , patient include study initiation appropriate lipidlowering medication . 14 . Patients must accessible treatment followup . 15 . Patients must able understand investigational nature study give write informed consent prior study entry . 1 . Previous treatment bevacizumab antiangiogenesis agent . 2 . Previous treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . 3 . Patients major surgery significant traumatic injury within 4 week start study drug , patient recover side effect major surgery ( define require general anesthesia ) , patient may require major surgery course study . 4 . Minor surgical procedure ( exception placement portacath central venous access ) must complete least 7 day prior begin protocol treatment . 5 . Women pregnant lactating . 6 . Patients proteinuria screen demonstrate either : urine protein creatinine ( UPC ) ratio 1.0 screening OR urine dipstick proteinuria 2+ ( patient discover 2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection , must demonstrate 1 g protein/24 hour eligible ) 7 . Patients serious nonhealing wound , active ulcer , untreated bone fracture . 8 . Patients evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 9 . Patients history hematemesis hemoptysis ( define bright red blood ½ teaspoon per episode ) within 1 month prior study enrollment . 10 . History myocardial infarction unstable angina within 6 month begin treatment . 11 . Inadequately control hypertension ( define systolic blood pressure &gt; 150 mmHg /or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) . 12 . New York Heart Association ( NYHA ) class II great congestive heart failure ( CHF ) . 13 . Serious cardiac arrhythmia require medication . 14 . Significant vascular disease ( e.g. , aortic aneurysm require surgical repair , recent peripheral arterial thrombosis ) within 6 month prior Day 1 treatment . 15 . History stroke transient ischemic attack within 6 month prior begin treatment . 16 . Any prior history hypertensive crisis hypertensive encephalopathy . 17 . History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 begin treatment . 18 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . 19 . Any severe and/or uncontrolled medical condition condition could affect participation study : unstable angina pectoris , symptomatic CHF , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease severely impaired lung function uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN active ( acute chronic ) uncontrolled severe infection liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . 20 . Known hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) , excipients . 21 . Immunization attenuate live vaccine within 1 week study , anytime study treatment . 22 . Chronic , systemic treatment immunosuppressive agent . Patients require stable dose corticosteroid control cerebral edema eligible . Topical inhale steroid also allow . 23 . Known human immunodeficiency virus ( HIV ) infection . 24 . Grapefruits , star fruit , seville orange , juice product , avoid . 25 . Drugs substance know inhibitor inducer isoenzyme CYP3A4 avoid . 26 . Use St. John 's Wort rifampicin . 27 . Concurrent severe , intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement . 28 . Mental condition would prevent patient comprehension nature , risk associate , study . 29 . Use nonapproved investigational agent within 4 week study entry . Patients may receive investigational anticancer treatment participate study . 30 . Other malignancy within last 3 year , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Avastin</keyword>
	<keyword>RAD001</keyword>
	<keyword>Meningioma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Brain</keyword>
</DOC>